BioNTech, DualityBio:Efficacy in HER2-Expressing, Recurrent Endometrial Cancer
- Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated patients with HER2-expressing, recurrent endometrial cancer, an area of high unmet medical need
- Data demonstrated clinically meaningful antitumor activity across all HER2 expression levels and a manageable safety profile, with centrallyi HER2-tested patients showing a confirmed objective response rate of 47.9% in all evaluable patients, 49.3% in patients with prior immune checkpoint inhibitor treatment, and a median progression-free survival of 8.1 months
- Largest trial to date to report results for a HER2-targeted antibody-drug conjugate in this indication supports potential of trastuzumab pamirtecan in real-world patient populations, including patients with lower HER2 expression levels and prior checkpoint inhibitor treatment
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.